Hualan vaccine, GEM listed in the immediate! A big probability will create a madness beyond the Wantai creature!

Read: Hualan Biological Subsidiary Hualan Vaccine is expected to be available this yearWith the announcement of the latest news, the much-watched Hualan biological subsidiary Hualan Vaccine is expected to be listed this year has been a nail in the coffin, GaoYu Capital and Morningside Fund before the IPO to enter together may become a good wordaccording to the current market for the vaccine company's heat, and Hualan biological company quality than Wantai, Kanghua more prominent, it is expected that Hualan vaccine after the market has a good chance to break the Wantai 26 upand and down the recordIHualan Vaccine GEM IPO has begun counseling, progressHualan BioVaccines Co., Ltdintends to initially issue shares in the A-share market and listed, is receiving guidance from Huatai United Securities Co., Ltd., has been in Henan Securities Regulatory Bureau on June 30, 2020 for the record of counselingThe company's guidance for the record of the basic situation to be publicized, accept the supervision of all sectors of societyThis is the first company in Henan to announce the spin-off listing after the official release of "Several Provisions on the Domestic Listing of Subsidiaries of Listed Companies" on December 13, 2019Hualan vaccine since its inception has been focused on vaccine research and development, production and sales, the current vaccine is listed influenza virus lysis vaccine, H1N1 influenza virus lysis vaccine, tetravalent influenza virus lysis vaccine, Group A group C meningococcal polysaccharide vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hanson yeast), is China's vaccine products industry more varieties, more specifications of one of the enterprises2, the spin-off listing review, Gao Yu and The Morning side fund jointly joined into theApril 21, 2020, Hualan Bio intends to split its holding subsidiary Hualan Vaccines as a whole into a limited company, after it will be separated to the Shenzhen Stock Exchange GEM listingAfter the spin-off is completed, Hualan Bioequity Structure will not change and will maintain control over Hualan Vaccinethrough this spin-off, Hualan Bio will further realize business focus, better focus on blood products business, hualan vaccine to become the company's research and development, production and sales business independent listing platform, and through GEM financing to enhance the financial strength, to achieve the vaccine business sector bigger and strongerThe spin-off will further enhance the company's overall market capitalization and enhance the profitability and overall competitiveness of the company and its subsidiariesafter the spin-off listing, Hualan vaccine will realize the direct docking with the capital market, give play to the function and advantages of direct financing of the capital market, broaden the financing channels, improve financing flexibility, improve financing efficiency, so as to effectively reduce the cost of capital, for Hualan vaccine to provide adequate fundsIn the future, Hualan vaccine can use the capital market platform for industrial mergers and acquisitions and other capital operations, further expand the scope of business, enrich product lines, to achieve leapfrog developmentMarch 27, 2020, Hong Kong Kekang intends to use the overall valuation of 13.8 billion yuan of vaccine company as the basis for the transfer of its 15% stake in the vaccine company, of which Henan GaoyiYing Enterprise Management Consulting Partnership (Limited Partnership) (hereinafter referred to as "Gao Ying") has been granted a 9% stake in the vaccine company, and xinxiang ChenQiMing Management Consulting Partnership ("Morning Qiming" ( " On March 26, 2020, Hong Kong Kekang signed an equity transfer agreement with Gao Yuying and Chenyu Qiming with effective conditions, and it is proposed to transfer 9% of the equity of the vaccine company (the corresponding capital contribution of 9 million yuan) to Gao Yuying at a price of 124,200 yuan, and to transfer 6% of the equity interest of the vaccine company (6 million yuan corresponding to the vaccine company) to Chen's Qiming at a price of 828 million yuanHualan vaccine equity structure is as follows:Hualan vaccine in the last three years consolidated profit table main data are as follows:three, pipeline at a glance: influenza vaccine expansion is the largest point of view
Hualan vaccine was established in 2005, the layout of the vaccine business has been 15 years, has now become China's largest influenza virus lysis vaccine production baseIn recent years, the company based on blood products, the development of a diversified product portfolio, further strengthen the dominant position of blood products, quickly expand the size of the vaccine industryThe company currently has four main vaccine products: influenza virus lysate vaccine, recombinant hepatitis B vaccine (Hanson yeast), ACYW135 group meningococcal polysaccharide vaccine and Influenza A H1N1 influenza virus lysis vaccine2018, the company's four-price flu vaccine was approved for the marketDue to the more comprehensive coverage of the four-price influenza vaccine, while overlaying the high incidence of influenza epidemic in China since 2017, the company's four-price influenza vaccine in 2018-2019 to achieve rapid release, sales in 2019 more than 8 million units, an increase of more than 60% year-on-year, for the company to bring significant performance flexibilityThe company is China's largest influenza vaccine production base, but also the first, the world's fifth through the influenza vaccine WHO pre-certification enterprises, product quality industry leaderdomestic influenza epidemic is increasing year by year, awareness is expected to improve, more regions will be vaccines into immunization programs or health insurance coverage, penetration is expected to increaseIt is expected that the domestic four-price influenza vaccine space will reach 11 billion yuan plus, the current influenza market size of 2 billion yuan plus, with 5 times the growth spaceHualan vaccine is expected to maintain a dominant position in the influenza vaccine market, occupy ingested the influenza market 35%-40% of the share, the company's influenza vaccine revenue scale is expected to reach about 4 billion yuan, the expected net profit margin of 30%-35%, corresponding to net profit in 12-14 billion yuan, if 40 times the valuation of Hualan biological four-price influenza vaccine valuation space in 48 billion-56 billion yuanwith the increase of four-price influenza vaccine suppliers and the release of production capacity, the four-price may partially replace the trivalent, the proportion of gradually increasedAbout 36 million units were issued in 2019, of which about $9.7 million were issuedAssuming that After Wuhan Institute and Beijing Kexing are approved, Hualan, Jindick, Wuhan Institute, Beijing Kexing four-price supply capacity will reach 35-37 million left, with the increase of four-price influenza vaccine suppliers, the four-price will replace the trivalent, the proportion of gradually increased conclusion: What will the market value of The Hualan vaccine rise to after it goes on the market? I'm sure we'll soon see the answer given by Mr Market!